StockNews.com started coverage on shares of Agile Therapeutics (NASDAQ:AGRX – Get Rating) in a report issued on Tuesday morning. The firm issued a hold rating on the specialty pharmaceutical company's stock.

Agile Therapeutics Trading Up 6.5 %

Shares of AGRX opened at $0.20 on Tuesday. The firm's 50-day moving average is $0.24 and its two-hundred day moving average is $0.55. Agile Therapeutics has a twelve month low of $0.18 and a twelve month high of $26.40. The firm has a market capitalization of $8.16 million, a P/E ratio of -0.01 and a beta of 1.15.

Institutional Trading of Agile Therapeutics

Several large investors have recently modified their holdings of the business. BlackRock Inc. grew its position in shares of Agile Therapeutics by 1.1% in the first quarter. BlackRock Inc. now owns 1,523,758 shares of the specialty pharmaceutical company's stock valued at $319,000 after purchasing an additional 16,104 shares during the last quarter. Jane Street Group LLC acquired a new stake in shares of Agile Therapeutics in the second quarter valued at approximately $108,000. Finally, Renaissance Technologies LLC grew its position in shares of Agile Therapeutics by 281.3% in the first quarter. Renaissance Technologies LLC now owns 621,200 shares of the specialty pharmaceutical company's stock valued at $130,000 after purchasing an additional 458,300 shares during the last quarter. 19.94% of the stock is currently owned by institutional investors and hedge funds.

Agile Therapeutics Company Profile

Agile Therapeutics, Inc, a women's healthcare company, researches, develops, and commercializes prescription contraceptive products for women in the United States. Its lead product is Twirla, also known as AG200-15, a once-weekly prescription combination hormonal contraceptive patch. The company is also developing a pipeline of Twirla line extensions and other products, including AG200-15 Extended Regimen (ER), a regimen that allows a woman to have four episodes of withdrawal bleeding per year; AG200-15 smaller patch (SmP), which is a regimen designed to provide shorter and lighter withdrawal bleeds, and enhance contraceptive efficacy; AG200-15 ER SmP, a regimen to allow a woman to extend the length of her contraceptive cycle, as well as have shorter and lighter withdrawal bleeding episodes per year; and P-Patch, a progestin-only contraceptive patch intended for use by women who are unable or unwilling to take estrogen.

Further Reading

• Get a free copy of the StockNews.com research report on Agile Therapeutics (AGRX)
• Why the Cracker Barrel Selloff Looks Overcooked
• Coinbase Global Stock is a Falling Meat Cleaver
• It's Still Too Soon to Shop for Kohl's Stock
• Three Small-Cap Biotech Stocks to Consider Now
• What To Expect From The Q4 Earnings Reporting Season

Receive News & Ratings for Agile Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Agile Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.